Rollins-Raval and coworkers have confirmed these findings and have reported CD123 overexpression (by immunohistochemistry) in 83% of FLT3-ITD-mutaed AMLs and in 62% of AML cases with mutated NPM1 [56]. The gene discussed is FLT3; the disease is acute myeloid leukemia.